Elmiron Vision Loss Lawsuit
Elmiron (pentosan polysulfate sodium), prescribed for interstitial cystitis, has been linked to pigmentary maculopathy — a serious retinal condition that causes vision loss. Lawsuits target Janssen Pharmaceuticals (Johnson & Johnson).
Defendant: Janssen Pharmaceuticals (Johnson & Johnson) | MDL 2973 — District of New Jersey (Judge Brian R. Martinotti).
Key Facts
Who Qualifies
Individuals who took Elmiron for interstitial cystitis (IC) and were later diagnosed with pigmentary maculopathy or other retinal damage.
Related Injuries
- Pigmentary maculopathy
- Vision loss
- Blurred vision
- Difficulty reading
- Dark spots in vision
- Difficulty adapting to low light
- Legal blindness
Settlement Status
No global settlement has been reached. Cases continue to be consolidated in federal court.
Learn More About This Lawsuit
Elmiron Vision Loss Lawsuit Overview
Everything you need to know about the Elmiron lawsuit — pigmentary maculopathy, vision loss, and Janssen Pharmaceuticals litigation.
Do I Qualify for the Elmiron Lawsuit?
Find out if you qualify for the Elmiron vision loss lawsuit. Eligibility for pigmentary maculopathy claims.
Elmiron Lawsuit Settlement Amounts — April 2026 Update
Latest information on Elmiron lawsuit settlements, expected timelines, and case value projections for vision loss claims.
Elmiron Lawsuit FAQ
Frequently asked questions about the Elmiron vision loss lawsuit — eligibility, eye damage, and compensation.
You May Also Qualify For
You may also qualify for these active lawsuits:
ATTORNEY ADVERTISING. This website may be considered attorney advertising in some jurisdictions.
This website is for informational purposes only and does not constitute legal advice. No attorney-client relationship is formed by using this site or submitting a contact form. Prior results do not guarantee a similar outcome.
Free Case Review
Find out if you may qualify for compensation. No cost, no obligation.
ATTORNEY ADVERTISING. This website may be considered attorney advertising in some jurisdictions.